New Peptide Drug Loses Weight Like GLP-1 Drugs but Through Energy Burning, Not Appetite Loss
The modified prolactin-releasing peptide NN501 reduced body weight comparably to GLP-1 drugs but primarily through sustained energy expenditure and fatty-acid oxidation rather than appetite suppression, with slower weight regain after discontinuation.
Quick Facts
What This Study Found
NN501 reduced body weight comparably to GLP-1 RAs but with only modest food intake reduction, primarily through increased energy expenditure and fatty-acid oxidation, with more gradual weight regain and no compensatory hyperphagia after discontinuation.
Key Numbers
How They Did This
Preclinical study of NN501 (GPR10/NPFFR2 agonist) in mice, comparing weight loss mechanisms to GLP-1 receptor agonism using body weight, food intake, energy expenditure, fatty-acid oxidation, and post-treatment weight regain assessments.
Why This Research Matters
Weight regain is the biggest limitation of current GLP-1 drugs. A peptide that maintains weight loss through energy burning rather than appetite suppression could provide more durable results.
The Bigger Picture
This identifies a new peptide receptor pathway for obesity that could either replace or synergize with GLP-1 drugs, potentially solving the weight regain problem.
What This Study Doesn't Tell Us
Mouse model only. Human GPR10/NPFFR2 biology may differ. Long-term effects and safety profile unknown. Not tested in combination with GLP-1 drugs.
Questions This Raises
- ?Would combining NN501 with GLP-1 drugs produce additive weight loss?
- ?Does NN501 maintain metabolic improvements during weight regain?
- ?Is the human GPR10/NPFFR2 system a viable drug target?
Trust & Context
- Key Stat:
- Different mechanism NN501 loses weight through energy burning, not appetite suppression — fundamentally different from GLP-1 drugs
- Evidence Grade:
- Preclinical study with mechanistic characterization. Novel peptide target with promising but early-stage evidence.
- Study Age:
- Published in 2025.
- Original Title:
- Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.
- Published In:
- Cell metabolism, 38(1), 100-114.e6 (2026)
- Authors:
- Feetham, Claire H, Groom, Sam, John, Linu M(2), Christoffersen, Berit Ostergaard, Collabolletta, Valeria, Lyons, David, Adamson, Antony, Lundh, Sofia, Gerstenberg, Marina Kjærgaard, Tang-Christensen, Mads, Conde-Frieboes, Kilian W, Secher, Anna, Kruse Hansen, Ann Maria, Luckman, Simon M
- Database ID:
- RPEP-15159
Evidence Hierarchy
Frequently Asked Questions
How is this different from Ozempic?
Ozempic works mainly by reducing appetite. This new peptide (NN501) works by burning more calories and fat. When you stop Ozempic, hunger rebounds and weight returns quickly. When NN501 is stopped, weight comes back more slowly without the rebound overeating.
Could this solve the weight regain problem?
Potentially. By maintaining fat-burning even as treatment effects fade, NN501 may prevent the rapid weight regain that limits current GLP-1 drugs. It could also be combined with GLP-1 drugs for dual-mechanism weight loss.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15159APA
Feetham, Claire H; Groom, Sam; John, Linu M; Christoffersen, Berit Ostergaard; Collabolletta, Valeria; Lyons, David; Adamson, Antony; Lundh, Sofia; Gerstenberg, Marina Kjærgaard; Tang-Christensen, Mads; Conde-Frieboes, Kilian W; Secher, Anna; Kruse Hansen, Ann Maria; Luckman, Simon M. (2026). Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.. Cell metabolism, 38(1), 100-114.e6. https://doi.org/10.1016/j.cmet.2025.10.021
MLA
Feetham, Claire H, et al. "Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.." Cell metabolism, 2026. https://doi.org/10.1016/j.cmet.2025.10.021
RethinkPeptides
RethinkPeptides Research Database. "Analog of prolactin-releasing peptide reduces body weight pr..." RPEP-15159. Retrieved from https://rethinkpeptides.com/research/feetham-2026-analog-of-prolactinreleasing-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.